litlas
Log inCreate account

James N. Atkins

Active 1998–2021

55
Papers
26,324
Citations
51
h-index
55
i10-index

Citations

Citations per year for James N. Atkins1998: 4 citations1999: 47 citations2000: 76 citations2001: 104 citations2002: 96 citations2003: 104 citations2004: 143 citations2005: 141 citations2006: 134 citations2007: 182 citations2008: 162 citations2009: 191 citations2010: 233 citations2011: 240 citations2012: 247 citations2013: 248 citations2014: 216 citations2015: 224 citations2016: 204 citations2017: 205 citations2018: 168 citations2019: 616 citations2020: 652 citations2021: 501 citations2022: 369 citations2023: 309 citations2024: 374 citations2025: 147 citations2026: 10 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,085 citing papers, 32.2% of this breakdownChina: 608 citing papers, 6.3% of this breakdownUnited Kingdom: 603 citing papers, 6.3% of this breakdownItaly: 577 citing papers, 6% of this breakdownCanada: 446 citing papers, 4.7% of this breakdownGermany: 413 citing papers, 4.3% of this breakdownFrance: 393 citing papers, 4.1% of this breakdownSpain: 275 citing papers, 2.9% of this breakdownNetherlands: 263 citing papers, 2.7% of this breakdownAustralia: 258 citing papers, 2.7% of this breakdownJapan: 251 citing papers, 2.6% of this breakdownBelgium: 211 citing papers, 2.2% of this breakdown
0%32.2%Other 23%

Institutions

Fields

  • Medicine65.2%
  • Biochemistry, Genetics and Molecular Biology28.8%
  • Immunology and Microbiology1.2%
  • Computer Science0.7%
  • Pharmacology, Toxicology and Pharmaceutics0.7%
  • Nursing0.5%
  • Other2.9%

Topics

  • Breast Cancer Treatment Studies6.3%
  • Colorectal Cancer Treatments and Studies4.5%
  • Estrogen and related hormone effects3.9%
  • HER2/EGFR in Cancer Research3.4%
  • Cancer Genomics and Diagnostics2.5%
  • Colorectal Cancer Surgical Treatments2.5%
  • Other76.9%

Coauthors

All papers

Open in search
  1. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

    Authors: Sandra P. D’Angelo, Michelle R. Mahoney, Brian Andrew Van Tine, James N. Atkins, Mohammed Milhem, Balkrishna Jahagirdar, Cristina R. Antonescu, Elise Horvath, William D. Tap, Gary K. Schwartz, Howard Streicher - The Lancet Oncology 2018 cited by 748

  2. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer

    Authors: Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A. Meyerhardt, Deborah Schrag, Claire Greene, Bert H. O’Neil, James N. Atkins, Scott Berry, Blasé N. Polite, Eileen M. O’Reilly, Richard M. Goldberg, Howard S. Höchster, Richard L. Schilsky, Monica M. Bertagnolli, Anthony B. El-Khoueiry, Peter J. Watson, Al B. Benson, Daniel Mulkerin, Robert J. Mayer, Charles D. Blanke - JAMA 2017 cited by 893

  3. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

    Authors: Louis Fehrenbacher, Reena S. Cecchini, Charles E. Geyer, Priya Rastogi, Joseph P. Costantino, James N. Atkins, John Crown, Jonathan Polikoff, Jean-François Boileau, Louise Provencher, Christopher Stokoe, Timothy D. Moore, André Robidoux, Patrick J. Flynn, Virginia F. Borges, Kathy S. Albain, Sandra M. Swain, Soonmyung Paik, Eleftherios P. Mamounas, Norman Wolmark - Journal of Clinical Oncology 2019 cited by 420

  4. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Edith A. Perez, John A. Olson, JoAnne Zujewski, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Peter M. Ravdin, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, James N. Atkins, Jeffrey L. Berenberg, George W. Sledge - New England Journal of Medicine 2015 cited by 1,439

  5. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

    Authors: Bernard Fisher, Joseph P. Costantino, D. Lawrence Wickerham, Carol Redmond, Maureen Kavanah, Walter M. Cronin, Victor G. Vogel, André Robidoux, Nikolay Dimitrov, James N. Atkins, Mary B. Daly, Samuel Wieand, Elizabeth Tan-Chiu, Leslie G. Ford, Norman Wolmark, other National Surgical Adjuvant Breast, Bowel Project Investigators - JNCI Journal of the National Cancer Institute 1998 cited by 5,508

  6. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

    Authors: Federico Innocenti, Fang‐Shu Ou, Xueping Qu, Tyler Zemla, Donna Niedzwiecki, Rachel Tam, Shilpi Mahajan, Richard M. Goldberg, Monica M. Bertagnolli, Charles D. Blanke, Hanna K. Sanoff, James N. Atkins, Blasé N. Polite, Alan P. Venook, Heinz‐Josef Lenz, Omar Kabbarah - Journal of Clinical Oncology 2019 cited by 323

  7. Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07

    Authors: J. Philip Kuebler, H. Samuel Wieand, Michael J. O’Connell, Roy E. Smith, Linda H. Colangelo, Greg Yothers, Nicholas J. Petrelli, Michael Findlay, Thomas E. Seay, James N. Atkins, John L. Zapas, J. Wendall Goodwin, Louis Fehrenbacher, Ramesh K. Ramanathan, Barbara A. Conley, Patrick J. Flynn, Gamini S. Soori, Lauren K. Colman, Edward A. Levine, Keith S. Lanier, Norman Wolmark - Journal of Clinical Oncology 2007 cited by 1,053

  8. Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

    Authors: Edward H. Romond, Jong‐Hyeon Jeong, Priya Rastogi, Sandra M. Swain, Charles E. Geyer, Michael S. Ewer, Vikas Rathi, Louis Fehrenbacher, Adam Brufsky, Catherine A. Azar, Patrick J. Flynn, John L. Zapas, Jonathan Polikoff, Howard M. Gross, David D. Biggs, James N. Atkins, Elizabeth Tan-Chiu, Ping Zheng, Greg Yothers, Eleftherios P. Mamounas, Norman Wolmark - Journal of Clinical Oncology 2012 cited by 519

  9. Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

    Authors: Bernard Fisher, Joseph P. Costantino, D. Lawrence Wickerham, Reena S. Cecchini, Walter M. Cronin, André Robidoux, Therese B. Bevers, Maureen Kavanah, James N. Atkins, Richard G. Margolese, Carolyn D. Runowicz, Joan James, Leslie G. Ford, Norman Wolmark - JNCI Journal of the National Cancer Institute 2005 cited by 1,335

  10. The Influence of Finasteride on the Development of Prostate Cancer

    Authors: Ian M. Thompson, Phyllis J. Goodman, Catherine M. Tangen, M. Scott Lucia, Gary J. Miller, Leslie G. Ford, Michael M. Lieber, R. Duane Cespedes, James N. Atkins, Scott M. Lippman, Susie M. Carlin, Anne Ryan, Connie M. Szczepanek, John J. Crowley, Charles A. Coltman - New England Journal of Medicine 2003 cited by 2,509

  11. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer

    Authors: Victor G. Vogel, Joseph P. Costantino, D. Lawrence Wickerham, Walter M. Cronin, Reena S. Cecchini, James N. Atkins, Therese B. Bevers, Louis Fehrenbacher, Eduardo R. Pajon, James L. Wade, André Robidoux, Richard G. Margolese, Joan James, Carolyn D. Runowicz, Patricia A. Ganz, Steven E. Reís, Worta McCaskill‐Stevens, Leslie G. Ford, V. Craig Jordan, Norman Wolmark, for the National Surgical Adjuvant Breast and Bowel Project - Cancer Prevention Research 2010 cited by 639

  12. Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors

    Authors: David S. Hong, Olivier Rixe, Vi K. Chiu, Patrick M. Forde, Tomislav Dragovich, Yanyan Lou, Asha Nayak-Kapoor, Rom Leidner, James N. Atkins, Agron Collaku, Floyd E. Fox, Margaret A. Marshall, Anthony J. Olszanski - Clinical Cancer Research 2021 cited by 41

  13. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

    Authors: André Robidoux, Gong Tang, Priya Rastogi, Charles E. Geyer, Catherine A. Azar, James N. Atkins, Louis Fehrenbacher, Harry D. Bear, Louis Baez-Diaz, Shakir Sarwar, Richard G. Margolese, William B. Farrar, Adam Brufsky, Henry R. Shibata, Hanna Bandos, Soonmyung Paik, Joseph P. Costantino, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark - The Lancet Oncology 2013 cited by 386

  14. Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

    Authors: Philip A. Philip, Jacqueline Benedetti, Christopher L. Corless, Ralph Wong, Eileen M. O’Reilly, Patrick J. Flynn, Kendrith M. Rowland, James N. Atkins, B. Mirtsching, Saul E. Rivkin, Alok A. Khorana, Bryan Goldman, Cecilia M. Fenoglio‐Preiser, James L. Abbruzzese, Charles D. Blanke - Journal of Clinical Oncology 2010 cited by 628

  15. Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

    Authors: Carmen J. Allegra, Greg Yothers, Michael J. O’Connell, Saima Sharif, Nicholas J. Petrelli, Linda H. Colangelo, James N. Atkins, Thomas E. Seay, Louis Fehrenbacher, Richard M. Goldberg, Séamus O’Reilly, Luis Chu, Catherine A. Azar, Samia Lopa, Norman Wolmark - Journal of Clinical Oncology 2010 cited by 594

  16. Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

    Authors: Brian I. Rini, Susan Halabi, Jonathan E. Rosenberg, Walter M. Stadler, Daniel A. Vaena, San-San Ou, Laura Archer, James N. Atkins, Joel Picus, Piotr Czaykowski, Janice P. Dutcher, Eric J. Small - Journal of Clinical Oncology 2008 cited by 908

  17. Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

    Authors: Brian I. Rini, Susan Halabi, Jonathan E. Rosenberg, Walter M. Stadler, Daniel A. Vaena, Laura Archer, James N. Atkins, Joel Picus, Piotr Czaykowski, Janice P. Dutcher, Eric J. Small - Journal of Clinical Oncology 2010 cited by 791

  18. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

    Authors: Alan P. Venook, Donna Niedzwiecki, Federico Innocenti, Briant Fruth, Claire Greene, Bert H. O’Neil, James E. Shaw, James N. Atkins, Laura E. Horvath, Blasé N. Polite, Jeffrey A. Meyerhardt, Eileen M. O’Reilly, Richard M. Goldberg, Howard S. Höchster, Charles D. Blanke, Richard L. Schilsky, Robert J. Mayer, Monica M. Bertagnolli, Heinz‐Josef Lenz - Journal of Clinical Oncology 2016 cited by 333

  19. A Phase III, Double-Blind, Placebo-Controlled Prospective Randomized Clinical Trial of d-Threo-Methylphenidate HCl in Brain Tumor Patients Receiving Radiation Therapy

    Authors: J.M. Butler, L. Douglas Case, James N. Atkins, Bart Frizzell, George Sanders, Patricia Griffin, Glenn J. Lesser, Kevin P. McMullen, Richard P. McQuellon, Michelle Naughton, Stephen R. Rapp, Volker W. Stieber, Edward G. Shaw - International Journal of Radiation Oncology*Biology*Physics 2007 cited by 211

  20. Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405

    Authors: Brendan J. Guercio, Sui Zhang, Fang‐Shu Ou, Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, Bert H. O’Neil, James E. Shaw, Blasé N. Polite, Howard S. Höchster, James N. Atkins, Richard M. Goldberg, Kaori Sato, Kimmie Ng, Erin Van Blarigan, Robert J. Mayer, Charles D. Blanke, Eileen M. O’Reilly, Charles S. Fuchs, Jeffrey A. Meyerhardt - Journal of Clinical Oncology 2019 cited by 68

  21. Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer

    Authors: Harry D. Bear, Gong Tang, Priya Rastogi, Charles E. Geyer, André Robidoux, James N. Atkins, Luis Báez-Díaz, Adam Brufsky, Rita S. Mehta, Louis Fehrenbacher, James A. Young, Francis M. Senecal, Rakesh Gaur, Richard G. Margolese, Paul T. Adams, Howard M. Gross, Joseph P. Costantino, Sandra M. Swain, Eleftherios P. Mamounas, Normal Wolmark - New England Journal of Medicine 2012 cited by 469

  22. Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B

    Authors: Everett E. Vokes, James E. Herndon, Michael J. Kelley, M. Giulia Cicchetti, Nithya Ramnath, H. Barry Neill, James N. Atkins, Dorothy Watson, Wallace Akerley, Mark R. Green - Journal of Clinical Oncology 2007 cited by 473

  23. Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial

    Authors: Eleftherios P. Mamounas, Jong‐Hyeon Jeong, D. Lawrence Wickerham, Roy E. Smith, Peter Ganz, Stephanie R. Land, Andrea Eisen, Louis Fehrenbacher, William B. Farrar, James N. Atkins, Eduardo R. Pajon, Victor G. Vogel, Joan F. Kroener, Laura F. Hutchins, André Robidoux, James L. Hoehn, James N. Ingle, Charles E. Geyer, Joseph P. Costantino, Norman Wolmark - Journal of Clinical Oncology 2008 cited by 340

  24. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

    Authors: Bert H. O’Neil, Monica M. Bertagnolli, Daniel Mulkerin, Scott Berry, Eileen M. O’Reilly, Charles D. Blanke, Robert J. Mayer, Deborah Schrag, Claire Greene, Jeffrey A. Meyerhardt, James N. Atkins, Peter Watson, Blasé N. Polite, Al B. Benson, Howard S. Höchster, Donna Niedzwiecki, Richard L. Schilsky, Alan P. Venook, Heinz‐Josef Lenz, Federico Innocenti, Briant Fruth, Anthony B. El-Khoueiry, Richard M. Goldberg - 2020 cited by 96